Elisabetta Sauta,Marie Robin,Matteo Bersanelli,Erica Travaglino,Manja Meggendorfer,Lin-Pierre Zhao,Juan Carlos Caballero Berrocal,Claudia Sala,Giulia Maggioni,Massimo Bernardi,Carmen Di Grazia,Luca Vago,Giulia Rivoli,Lorenza Borin,Saverio D'Amico,Cristina Astrid Tentori,Marta Ubezio,Alessia Campagna,Antonio Russo,Daniele Mannina,Luca Lanino,Patrizia Chiusolo,Luisa Giaccone,Maria Teresa Voso,Marta Riva,Esther Natalie Oliva,Matteo Zampini,Elena Riva,Olivier Nibourel,Marilena Bicchieri,Niccolo’ Bolli,Alessandro Rambaldi,Francesco Passamonti,Victor Savevski,Armando Santoro,Ulrich Germing,Shahram Kordasti,Valeria Santini,Maria Diez-Campelo,Guillermo Sanz,Francesc Sole,Wolfgang Kern,Uwe Platzbecker,Lionel Ades,Pierre Fenaux,Torsten Haferlach,Gastone Castellani,Matteo Giovanni Della Porta

Abstract:PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M. METHODS A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed. RESULTS IPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 v 0.74 for overall survival and 0.89 v 0.76 for leukemia-free survival, respectively). This was true even in those patients without detectable gene mutations. Compared with the IPSS-R based stratification, the IPSS-M risk group changed in 46% of patients (23.6% and 22.4% of subjects were upstaged and downstaged, respectively). In patients treated with hematopoietic stem cell transplantation (HSCT), IPSS-M significantly improved the prediction of the risk of disease relapse and the probability of post-transplantation survival versus IPSS-R (concordance was 0.76 v 0.60 for overall survival and 0.89 v 0.70 for probability of relapse, respectively). In high-risk patients treated with hypomethylating agents (HMA), IPSS-M failed to stratify individual probability of response; response duration and probability of survival were inversely related to IPSS-M risk. Finally, we tested the accuracy in predicting IPSS-M when molecular information was missed and we defined a minimum set of 15 relevant genes associated with high performance of the score. CONCLUSION IPSS-M improves MDS prognostication and might result in a more effective selection of candidates to HSCT. Additional factors other than gene mutations can be involved in determining HMA sensitivity. The definition of a minimum set of relevant genes may facilitate the clinical implementation of the score.

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes